<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, June 25, 2018 (HealthDay News) — For Japanese patients with type 2 diabetes, low-dose aspirin is not associated with reduced cancer incidence, except in those younger than 65 years, according to a study published online June 16 in Diabetes Care<\/i>.<\/p>\n
Sadanori Okada, M.D., from Nara Medical University in Kashihara, Japan, and colleagues conducted a post-trial follow-up of the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes trial. A total of 2,536 patients with type 2 diabetes were randomized to receive aspirin (81 or 100 mg daily) or no aspirin. Participants were followed from the trial end in 2008 until 2015.<\/p>\n
The researchers found that 318 cancers occurred during a median follow-up of 10.7 years. There was no significant difference between the aspirin and no-aspirin groups in terms of cancer incidence (hazard ratio, 0.92; 95 percent confidence interval, 0.73 to 1.14; P = 0.4). Aspirin did not affect cancer incidence in men, women, or those aged \u226565 years in subgroup analyses. There was a decrease in cancer incidence associated with aspirin use among those aged <65 years (hazard ratio, 0.67; 95 percent confidence interval, 0.44 to 0.99; P = 0.048). Aspirin was associated with significantly reduced cancer incidence in participants aged <65 years after adjustment for sex, hemoglobin A1c, smoking status, and administration of metformin and statins (adjusted hazard ratio, 0.66; 95 percent confidence interval, 0.43 to 0.99; P = 0.04).<\/p>\n
“Low-dose aspirin did not reduce cancer incidence in Japanese patients with type 2 diabetes,” the authors write.<\/p>\n
Several authors disclosed financial ties to the pharmaceutical and medical device industries.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n